CytRx (CYTR) to Present Statistically Significant Evidence of Arimoclomol's Ability to Protect Experimental Animals from Effects of Hypoxia
More News related to CYTR
- CytRx Announces Publication of Paper Stating that Chaperone Amplification Represents a 'Significant Strategy' in Anti-aging Pharmaceutical Design
- CytRx Fortifies Executive Suite with Addition of Chief Medical Officer
- CytRx (CYTR) and Cephalon (CEPH) Oncology Therapies to be Evaluated as Treatment for Relapsed Acute Promyelocytic Leukemia
- CytRx and Cephalon Oncology Therapies to be Evaluated as Treatment for Relapsed Acute Promyelocytic Leukemia
- Morning Movers 9/10: DVAX, DARA, GNBT, XRTX, NCS Higher; PLAB, SEH, NAV Lower
CytRx Corporation (NASDAQ: CYTR) announced that an experimental animal trial produced statistically significant evidence that the company's chaperone amplifying drug candidate arimoclomol provided protection from the detrimental cognitive and sensorimotor effects of low atmospheric oxygen (hypoxia) that occurs at high altitudes. Data from this trial will be presented in a poster, "A heat-shock protein co-inducer treatment improves behavioral performance in rats exposed to hypoxia," on July 9 at the 37th Annual International Society on Oxygen Transport to Tissue (ISOTT) Conference, being held in Cleveland, Ohio.
Sign up at EasyStockAlerts for free to see your stock news before it breaks to the rest of the public!
Related Categories
Corporate NewsFDA
Stocks Mentioned
+0.05Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
